Of all the conditions ibogaine gets discussed for, smoking has the most elegant theoretical case. The receptor ibogaine blocks most potently is a nicotinic acetylcholine receptor, the same family nicotine acts on. If a drug sits inside the channel of a nicotinic receptor, using it against nicotine dependence is an obvious thought.
The theoretical case does not survive contact with the evidence in the form people expect. No human study has tested ibogaine for smoking. The rodent nicotine data in this research family concerns an analog rather than ibogaine, and ibogaine's own documented effects on drug self-administration in animals do not include nicotine. This entry sets out what is actually there.
The short answer
There is no evidence that ibogaine helps people stop smoking. There is a plausible receptor mechanism, there is rodent evidence for a related compound, and there is nothing in humans. Anyone presenting ibogaine as a smoking treatment is extrapolating across a species gap and a compound gap at the same time.
The distinction being drawn matters because the two gaps compound rather than add. Extrapolating from rats to humans is a routine uncertainty in pharmacology, and it is usually acknowledged. Extrapolating from one compound to another is a second uncertainty of a similar size. Doing both at once, and then presenting the result as evidence for a treatment, produces a claim several steps removed from anything that has been measured.
Why the receptor makes it plausible
The alpha3beta4 nicotinic receptor is the best-characterised target ibogaine has. Work on human alpha3beta4 receptors expressed in cells found that ibogaine blocked receptor-driven calcium influx about nine times more potently than phencyclidine, and bound a single site inside the ion channel with a dissociation constant of 0.46 micromolar [1].
That figure matters because it is the lowest in ibogaine's binding profile. Most of its documented receptor interactions occur at micromolar concentrations [2], which is relatively weak. Sub-micromolar binding at a specific site within a channel is a sharper interaction, and it is the one place where ibogaine's affinity approaches a concentration plausibly reached in treatment.
The authors also found binding slightly tighter when the receptor was in its desensitised state, and suggested this might hold the receptor desensitised for longer [1]. A receptor held desensitised responds less to its natural signal, and by extension less to nicotine. That is a coherent mechanistic story for a smoking effect.
It is worth being clear what that study is. It is a cell-based experiment using human receptors, which establishes the molecular interaction well and says nothing about behaviour in any animal, let alone a person.
Some context on the receptor itself helps explain the interest. The alpha3beta4 subtype is not the one that mediates most of nicotine's rewarding effects in the brain, which is generally attributed to a different subtype concentrated in reward pathways. Alpha3beta4 receptors are found in autonomic ganglia and in specific brain regions including the habenula, an area implicated in aversion and in nicotine withdrawal. A drug acting there might plausibly affect the aversive side of dependence rather than the rewarding side, which is a different and more interesting proposition than simply blocking nicotine's effects.
What ibogaine reduced in animals
Ibogaine has a reasonably consistent rodent record on drug self-administration, and the specific list is where this question turns. The 2019 review summarises it as reducing self-administration of morphine, heroin, cocaine and alcohol, and reducing precipitated withdrawal signs [2].
Nicotine is not in that list. The compounds ibogaine has been shown to reduce self-administration of in rodents are opioids, cocaine and alcohol. Given that the nicotinic receptor is ibogaine's sharpest documented target, the absence of nicotine from its own behavioural record is a genuinely odd feature of this literature, and it is not resolved by assuming the experiment would have worked.
Two readings of that absence are available and neither supports a smoking claim. Either the experiment was done and did not produce a reportable effect, in which case the silence is informative in the unhelpful direction, or it was never done, in which case there is simply no evidence. Absence of a published result in a literature this well explored is not neutral, and it certainly cannot be counted as support.
The analog data on nicotine
The nicotine evidence belongs to 18-MC, an ibogaine analog developed to retain the anti-addictive effects without the tremor, cerebellar toxicity and cardiac channel block [5]. Crucially, 18-MC is most potent and somewhat selective as an alpha3beta4 nicotinic antagonist, which makes it a more targeted probe of that receptor than ibogaine is [3].
In animal models, 18-MC reduced intravenous morphine, cocaine, methamphetamine and nicotine self-administration and oral alcohol and nicotine intake, attenuated opioid withdrawal, did not affect responding for water, and produced no apparent toxicity. Low-dose combinations of other alpha3beta4 blockers reproduced those effects [3]. That last point is the strongest part of the mechanistic argument, since reproducing an effect with different compounds hitting the same receptor is good evidence that the receptor is responsible.
A later study tested oral 18-MC directly at 10, 20 and 40 milligrams per kilogram. The 40 milligram dose reduced nicotine self-administration, but only in rats with lower baseline intake, while all doses reduced alcohol intake dose-dependently in both sexes [4].
Read carefully, that is a modest nicotine result. The effect appeared at the highest of three doses and only in a subgroup defined by how much they were already taking, whereas the alcohol effect was dose-dependent and general. Even within the analog literature, nicotine is the weaker finding.
If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.
Find a providerWhy the analog data does not transfer
Treating 18-MC findings as ibogaine findings would be a straightforward error, and the reason is in the chemistry. 18-MC lacks ibogaine's tremor, cerebellar neurotoxicity and hERG channel block [5], and is more selective at the alpha3beta4 receptor [3]. The two compounds therefore differ precisely in the properties that matter, which is the entire point of having developed the analog.
A more selective compound acting at a receptor is the better test of what that receptor does, and a result obtained with it does not establish that a dirtier compound acting at the same receptor among many others will do the same thing. Ibogaine engages NMDA, opioid, serotonin and sigma receptors and the monoamine transporters alongside the nicotinic one [2], and those interactions do not switch off because a researcher is interested in nicotine.
18-MC also has no published efficacy results in humans for anything. Its registered phase 1 study in healthy volunteers enrolled 108 participants, completed in 2021, and has no results posted [8]. So the compound with the nicotine data has not been shown to work in people either.
The absence of human studies
No human trial, case series or observational cohort has examined ibogaine for smoking or nicotine dependence. A 2026 review of three decades of human ibogaine research, covering 24 studies and 38 case reports and series published between 1990 and early 2025, describes observational data suggesting benefit in opioid use disorder, post-traumatic stress disorder and polysubstance dependence [6]. Nicotine dependence is not among the indications with human data.
That absence is not an oversight waiting to be corrected. Research effort has concentrated where the observed effect is most distinctive and the existing treatments least adequate, and nicotine dependence has several approved pharmacological treatments with established safety profiles.
One further consideration concerns how smoking dependence actually behaves. It is characterised by very frequent dosing over many years, with relapse typically occurring gradually through environmental cues rather than through an acute withdrawal crisis. A single-dose intervention is best suited to a problem with an acute barrier to overcome, which is the logic behind its use in opioid withdrawal. For a condition where the difficulty is sustained cue-driven relapse over months, a single dose addresses the part of the problem that is least difficult.
The risk comparison for smoking
This is where the question effectively settles, and it does so on risk rather than on the mechanism. Smoking causes enormous harm over decades, and stopping is valuable. But the alternatives are well characterised, inexpensive and do not require cardiac monitoring.
Ibogaine does. In a closely screened Dutch series of 14 patients, maximum QT prolongation averaged 95 milliseconds, 7 of 14 passed 500 milliseconds, in 6 of 14 the abnormality persisted beyond 24 hours, and all 14 developed severe transient ataxia leaving them unable to walk unaided [7]. Accepting that profile for opioid dependence, a condition with high short-term mortality, is a defensible calculation. Accepting it to stop smoking, when nicotine replacement and approved medicines exist, is a different proposition entirely.
The duration of the experience bears on this too. A full dose produces a prolonged, intense psychoactive state lasting most of a day, which is a demanding intervention relative to the alternatives for this particular indication.
What would be needed
The sequence is not mysterious. Someone would have to test ibogaine itself on nicotine self-administration in rodents, which appears not to have been reported, and establish an effect. A human study would then need nicotine dependence as its entry criterion, a comparison group, and an objective endpoint such as biochemically verified abstinence rather than self-report.
Given that the nicotinic receptor is ibogaine's most potent target, that first rodent experiment is a conspicuous gap. Until it is filled, the receptor argument remains a reason to look rather than a finding, and the honest summary is that smoking is a plausible indication with no evidence behind it, and that the plausibility comes from chemistry rather than from any observation of people who smoke.
There is a final point about how these claims tend to be made. The nicotinic receptor evidence is genuine, specific and published, which makes it easy to cite and easy to misuse. A page can accurately report that ibogaine blocks a nicotine receptor, accurately report that a related compound reduced nicotine intake in rats, and leave a reader with the impression that ibogaine treats smoking, without stating a single false sentence. Recognising that pattern is more useful than checking individual facts, because the individual facts will generally hold up.
Frequently asked questions
Has ibogaine been tested for smoking?
Not in humans. A 2026 review of human ibogaine research describes observational data for opioid use disorder, post-traumatic stress and polysubstance dependence [6], and nicotine dependence is not among them.
Does ibogaine act on nicotine receptors?
Yes, and it is its sharpest documented interaction. Ibogaine binds a single site in the channel of the human alpha3beta4 nicotinic receptor at 0.46 micromolar and blocks calcium influx through it [1].
Did the rodent studies show reduced nicotine use?
For 18-MC, partly. Oral 18-MC at 40 milligrams per kilogram reduced nicotine self-administration in rats with lower baseline intake only, while all doses reduced alcohol intake [4]. Ibogaine's own rodent record covers morphine, heroin, cocaine and alcohol [2].
Why is the receptor argument not enough?
Because binding establishes a molecular interaction rather than a clinical effect, and ibogaine engages NMDA, opioid, serotonin and sigma receptors and the monoamine transporters alongside the nicotinic one [2]. A plausible mechanism indicates where it is worth looking, not what will actually be found there.
Can 18-MC findings be applied to ibogaine?
No. 18-MC is more selective at the alpha3beta4 receptor [3] and lacks ibogaine's tremor, cerebellar toxicity and cardiac channel block [5], so the compounds differ in exactly the respects that matter.
References
- Arias HR, Rosenberg A, Targowska-Duda KM, et al. 2010, Int J Biochem Cell Biol 42(9):1525-1535. doi:10.1016/j.biocel.2010.05.011. PMID 20684041. doi.org/10.1016/j.biocel.2010.05.011
- Marton S, Gonzalez B, Rodriguez-Bottero S, et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
- Maisonneuve IM, Glick SD. 2003, Pharmacol Biochem Behav 75(3):607-618. doi:10.1016/s0091-3057(03)00119-9. PMID 12895678. europepmc.org/article/MED/12895678
- Rezvani AH, Cauley MC, Slade S, Wells C, Glick S, Rose JE, Levin ED. 2016, Pharmacol Biochem Behav 150-151:153-157. doi:10.1016/j.pbb.2016.10.010. PMID 27984095. PMC6739120. europepmc.org/article/PMC/PMC6739120
- Iyer RN, Favela D, Zhang G, Olson DE. 2021, Nat Prod Rep 38(2):307-329. doi:10.1039/d0np00033g. PMID 32794540. PMC7882011. europepmc.org/article/PMC/PMC7882011
- Kervadec E, Bezo A, Serreau R, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. doi.org/10.1097/jcp.0000000000002197
- Knuijver T, Schellekens A, Belgers M, et al. 2022, Addiction 117(1). doi:10.1111/add.15448. PMC9292417. europepmc.org/article/PMC/PMC9292417
- ClinicalTrials.gov NCT04292197. "A Phase 1 Study of 18-Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers." Registry record. clinicaltrials.gov/study/NCT04292197